United States: President Obama Announces FDA Commissioner And Deputy Commissioner Appointments

The appointments signal significant challenges ahead; FDA compliance and enforcement actions are likely to increase substantially.

In his weekly radio address on March 14, 2009, President Barack Obama announced the appointment of Dr. Margaret "Peggy" Hamburg as commissioner-designate of the U.S. Food and Drug Administration (FDA), and of Dr. Joshua Sharfstein as principal deputy commissioner. Click here for more information. Dr. Hamburg's appointment requires Senate confirmation; Dr. Sharfstein's does not. These appointments were announced at the same time as President Obama announced the creation of a Cabinet-level interagency Food Safety Working Group intended to report back to him as soon as possible about ways to strengthen the nation's food safety system, whose weaknesses have been exposed so glaringly in the recent salmonella-contaminated peanut butter debacle and other incidents.

While President Obama focused on food safety in announcing the Hamburg and Sharfstein appointments, the problems confronting the incoming FDA commissioner and principal deputy commissioner range much more broadly. Perhaps most notably, these problems include an agency whose stature, credibility and morale have been seriously eroded as a consequence of a seemingly endless parade of perceived missteps. These range from drug safety concerns, typified most notably by the public health issues surrounding drugs such as Vioxx, to the current controversy about the integrity and independence of the entire medical device clearance and approval regime occasioned by anonymous complaints from concerned scientists in FDA's Center for Medical Devices and Radiological Health. Add to this the incessant congressional oversight that all of this has occasioned, and one can readily see why the new team at FDA has its work cut out for it.

Dr. Hamburg and Dr. Sharfstein each bring impressive credentials to their respective appointments. These were highlighted by President Obama in his radio address, and the press release accompanying the transcript of the President's remarks provides additional biographical details about each of them. Click here for more information. At the same time, one can reasonably ask whether the array of challenges facing FDA at this precarious moment in its more-than-100-year history are manageable by even these talented individuals. For example, Congress seems poised to give FDA jurisdiction over tobacco product. This will take an agency whose long-standing mission is to protect the public health into regulation of products that most people believe are fundamentally at odds with the public health. Whether this will ultimately erode FDA's core public health mission is anyone's guess. But it will divert significant time and attention from areas, such as food safety, that President Obama himself acknowledges require fixing.

Likewise, Congress is now considering legislation that would establish a pathway for the review and approval of follow-on versions of pioneer biologicals approved by FDA under the Public Health Service Act. This legislation has been identified as one centerpiece of the administration's overall health reform initiative. If enacted, as seems likely, follow-on biologics (FOB) legislation would require significant time and attention from senior FDA management to implement properly. It is speculated that Dr. Sharfstein would have primary responsibility over drugs and biologicals, whereas Dr. Hamburg would focus her attention to food safety and other high priority issues. Despite this division of responsibility, it seems apparent that, if confirmed, the new FDA commissioner will have to devote considerable personal time to implementation of an FOB regime and could not delegate all of this responsibility to the principal deputy commissioner without in some sense abdicating part of the mandate that would accompany her confirmation by the Senate. Moreover, FDA has significant unfinished business to attend to in its overall implementation of the Food and Drug Administration Act of 2007, particularly in connection with its authority to require Risk Evaluation and Mitigation Strategies (REMS). The scope of this new authority will be seriously tested in, among other contexts, FDA's recently announced call for a REMS for approved and already-marketed long acting opioid drugs that have significant potential for abuse. Indeed, FDA has already threatened to withdraw approval for these drugs unless the manufacturers themselves agree to develop and implement a single overarching REMS that would apply to all of them. Other significant challenges, such as the unwinding of the Bush administration's position on federal preemption of state law failure to warn lawsuits involving prescription drugs, in response to the Supreme Court of the United States' recent decision in the Levine case, will similarly require attention. In addition, FDA will need to address whether and to what extent it will regulate laboratory developed tests under its "medical device" authority. In turn, this will have significant implications for FDA's entire approach to "personalized medicine."

Perhaps most significantly for the regulated community, one can expect to see a substantial uptick in compliance and enforcement activity from a newly constituted Obama FDA led by Commissioner Hamburg and Principal Deputy Commissioner Sharfstein. Indeed, we have already seen an increase in enforcement in FDA's regulation of pharmaceutical and biotech advertising and promotion in anticipation of the impending management changes. Other areas that are likely to be the focus of substantially enhanced compliance and enforcement action by FDA include bioresearch monitoring, good manufacturing practices, medical device modifications without prior FDA clearance or approval, and off-label promotion of both pharmaceuticals/biologicals and medical devices, among others. In this context, it seems important for FDA-regulated entities to take stock of where they stand on significant regulatory and legal issues of concern. McDermott Will & Emery can provide significant insight and assistance to clients in addressing FDA issues they are facing or likely to encounter going forward.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Related Topics
 
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions